SUPERNUS PHARMACEUTICALS, INC.
SUPNReported to SECin USCIK 0001356576Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 20. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Rubin JonathanSVP, Chief Medical Officer | Option exercise | nothing paid750 shares | Aug 14, 2026 | Rubin JonathanSVP, Chief Medical Officer | nothing paid | Option exercise | 750 | Aug 14, 2026 |
| Rubin JonathanSVP, Chief Medical Officer | Administrative | $16,905363 shares | Aug 14, 2026 | Rubin JonathanSVP, Chief Medical Officer | $16,905 | Administrative | 363 | Aug 14, 2026 |
| Rubin JonathanSVP, Chief Medical Officer | Option exercise | nothing paid750 shares | Aug 14, 2026 | Rubin JonathanSVP, Chief Medical Officer | nothing paid | Option exercise | 750 | Aug 14, 2026 |
| Mottola FrankSVP, Chief Tech. Ops. Officer | Option exercise | nothing paid1,650 shares | Aug 14, 2026 | Mottola FrankSVP, Chief Tech. Ops. Officer | nothing paid | Option exercise | 1,650 | Aug 14, 2026 |
| Mottola FrankSVP, Chief Tech. Ops. Officer | Administrative | $37,116797 shares | Aug 14, 2026 | Mottola FrankSVP, Chief Tech. Ops. Officer | $37,116 | Administrative | 797 | Aug 14, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and SUPERNUS PHARMACEUTICALS, INC. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.
Before 2025, these bars cover only the lobbying relationships that were still active in 2025 or later. Engagements that ended earlier are not included, so those years may be higher than shown.